Are you ready for data democratization? Test your rights, sharing preferences, and health-data choices.

Q1. Which statement best describes the difference between GDPR and HIPAA when it comes to personal health data?
- GDPR generally covers personal data, while HIPAA focuses on identifiable health information handled in the U.S. healthcare context.
- GDPR applies only to hospital records, while HIPAA applies to all personal data worldwide.
- GDPR and HIPAA are identical laws with the same coverage and individual rights.
- HIPAA gives broader control over all personal data than GDPR.
Answer: GDPR generally covers personal data, while HIPAA focuses on identifiable health information handled in the U.S. healthcare context. Explanation: GDPR can cover personal data broadly, whereas HIPAA is narrower and centers on protected health information handled by covered healthcare entities and business associates.
Q2. Which of the following is a GDPR right that allows a person, in qualifying circumstances, to ask for personal data to be deleted?
- The right to erasure
- The right to portability
- The right to object to direct marketing
- The right to automated profiling
Answer: The right to erasure. Explanation: The GDPR right to erasure is also called the right to be forgotten, although legal and public-interest exceptions can apply.
Q3. Which combination best reflects conditions that can increase willingness to share personal health data?
- Being informed about the sharing, knowing its purpose, having consent or an opt-out choice, and having independent oversight
- Being told nothing about the sharing and having no way to withdraw
- Allowing commercial profit to take priority over health benefits
- Removing all privacy protections while offering an unspecified reward
Answer: Being informed about the sharing, knowing its purpose, having consent or an opt-out choice, and having independent oversight. Explanation: Transparency, a clear reason for sharing, meaningful control, and independent review were important influences on willingness.
Q4. Which potential new users were generally preferred by respondents when personal health data were shared?
- National authorities and academic research projects
- Technology companies and advertisers
- Insurance companies and unrelated retailers
- Any organization, provided it offered payment
Answer: National authorities and academic research projects. Explanation: Respondents preferred national authorities and academic research projects as new users; pharmaceutical companies were viewed more favorably than technology companies on average.
Q5. Which privacy statement is most consistent with the research findings?
- People tend to support research sharing when data are pseudonymised, but genetic data raise extra concerns because they are uniquely identifying.
- Pseudonymisation guarantees that genetic data can always be made fully anonymous.
- Genetic data create no additional privacy concerns compared with other health data.
- People generally prefer sharing data only when it is impossible to know why it is being used.
Answer: People tend to support research sharing when data are pseudonymised, but genetic data raise extra concerns because they are uniquely identifying.. Explanation: Pseudonymisation can make research sharing more acceptable, but genetic information generally cannot be made fully anonymous.
Q6. What conclusion is supported by the retrieved evidence about the compensation, or “digital dividend,” offered for sharing self-tracked health data?
- The retrieved evidence does not report a compensation amount, whether payment increased willingness, or which payment arrangements people preferred.
- The study established a standard payment amount that most participants accepted.
- Payment was proven to be more important than trust, privacy, or control.
- Participants unanimously rejected all compensation for sharing health data.
Answer: The retrieved evidence does not report a compensation amount, whether payment increased willingness, or which payment arrangements people preferred. Explanation: The available evidence describes the compensation question as a separate consideration but does not provide those study findings, so no payment amount or effect should be assumed.

Are you ready for data democratization? Test your rights, sharing preferences,

Explore related topics